Epstein-Barr virus-latent membrane protein 1 expression has a favorable influence in the outcome of patients with Hodgkin's disease treated with chemotherapy

Leukemia and Lymphoma

Volumn 39, Issue 5-6, 2000, Pages 563-572

  Montalban, C ^a   Abraira, V ^a   Morente, M ^a   Acevedo, A ^a   Aguilera, B ^a   Bellas, C ^a   Fraga, M ^a   Garcia del Moral R ^a   Menarguez, J ^a   Oliva, H ^a   Sanchez Beato, M ^a   Piris, M A ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Bc1 2; Hodgkin's disease; LMP1 EBV; P53; Prognostic factors; Proliferative index; Rb

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CD15 ANTIGEN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; LATENT MEMBRANE PROTEIN 1; PREDNISONE; PROCARBAZINE; PROTEIN BCL 2; PROTEIN P53; RETINOBLASTOMA PROTEIN; VINCRISTINE;

ADULT; AGE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; FEMALE; HODGKIN DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SPAIN; TREATMENT OUTCOME;

EID: 0034488067     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190009113386     Document Type: Article

References (38)

1. Problems in Hodgkin's disease management
2. ABVD chemotherapy in the treatment of Hodgkin's disease
3. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD
4. ABVD in the treatment of Hodgkin's disease
5. Alternating Drug combinations in the treatment of advanced Hodgkin's disease
6. Alternating versus hybrid MOPP and ABVD combination in advanced Hodgkin's disease: Ten years results
7. BEACOPP, a new regimen for advanced Hodgkin's disease
8. Brief chemotherapy. Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: A preliminary report
9. High dose therapy for Hodgkin's disease
10. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially non-cross-resistant chemotherapy and intermediate-dose radiation therapy
11. Prognostic factors for positive surgical staging in patients with Hodgkin's disease
12. Tumor burden as the most important prognostic factor in early stage Hodgkin's disease
13. Toward comprehensive management tailored to prognostic factors of patients with clinical stage I and II in Hodgkin's disease. The ORTC Group Controlled Clinical Trials 1964-1987
14. Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin's disease
15. Prognostic role of serum beta 2-microglobulin in Hodgkin's disease
16. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease
17. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival
18. Serum level of the soluble form of CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome
19. A prognostic score for advanced Hodgkin's disease
20. Activated cytotoxic T-cells as prognostic marker in Hodgkin's disease
21. Expression of the p53 gene in Hodgkin's disease: Dissociation between immunohistochemistry and clinicopathological data
22. Low p53 and high bcl-2 expression in Reed-Sternberg cells predict poor clinical outcome for Hodgkin's disease: Involvement of apoptosis resistance?
23. Bcl-2 is frequently expressed in Hodgkin-Reed-Sternberg cells and is associated with inferior failure-free survival in Hodgkin's disease treated with ABVD
24. The impact of EBV, proliferation rate and bcl-2 expression in Hodgkin's disease in childhood
25. Influence of Epstein-Barr virus genomes on patient survival in Hodgkin's disease
26. Epstein-Barr virus association in classical Hodgkin's disease provides survival advantage to patients and correlates with higher expression of proliferation markers in Reed-Sternberg cells
27. The expression of the EBV-coded latent membrane protein-1 (LMP-1) in Reed-Sternberg cells of Hodgkin's disease (HD) is associated with higher serum IL-10 levels and inferior failure-free survival (FFS)
28. Effect of Epstein-Barr virus infection on response to chemotherapy and survival in Hodgkin's disease
29. Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression, high Ki67 proliferation index, and absence of Epstein-Barr virus-latent protein 1 expression
30. Retinoblastoma (Rb) gene product expression in lymphomas. Correlation with ki67 growth fraction
31. Anomalous retinoblastoma protein expression in Sternberg-Reed cells in Hodgkin's disease: A comparative study with p53 and ki67 expression
32. Conditioning diagnosis: Colinearity and weak data in regression
33. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease
34. T-cell recognition of Epstein-Barr virus associated lymphomas
35. The EBV-encoded LMP1 protein inhibits p53-triggered apoptosis but not growth arrest